feedback

Course Director

Michelle A. Fanale, MD
Michelle A. Fanale, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2017-Jul-13
Expiration Date:2018-Jul-12
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

In this activity, a lymphoma expert discusses the clinical relevance and role of CD30 expression in lymphomas, as well as the clinical utility and implications of current and emerging evidence on novel therapeutics for the management of CD30-expressing diseases.

Upon completion of this activity, participants should be better able to:
  • Summarize current guidelines on CD30 testing in different lymphoma settings, including T-cell NHL, B-cell NHL, and HL
  • Discuss updated clinical trial findings on novel agents for the management of CD30-expressing lymphoma
  • Select evidence-based treatment for patients with CD30-expressing lymphoma

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other clinicians involved in the treatment of patients with lymphoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 13, 2017 - July 12, 2018
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director
Michelle A. Fanale, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Department of Lymphoma / Myeloma
Houston, Texas

Michelle A. Fanale, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; and Spectrum Pharmaceuticals, Inc.
Grant/Research Support from Celgene Corporation; Bristol-Myers Squibb Company; Genentech, Inc.; Gilead; MedImmune; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Molecular Templates; Novartis Pharmaceuticals Corporation; and Seattle Genetics, Inc.
Honoraria from Plexus Ventures; Research To Practice; Seattle Genetics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Michelle A. Fanale, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Novel therapies such as antibody-drug conjugates, PI3K inhibitors, ALK inhibitor, and farnesyltransferase inhibitor, among others in the management of CD30-expressing lymphomas.

CME Reviewer
Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Seattle Genetics.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.